Hemab Therapeutics Holdings, Inc. (COAG)
Market Closed
15 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
32. 52
+2.58
+8.6172%
$
1.39B Market Cap
- P/E Ratio
- Div Yield
478,279 Volume
- Eps
$ 29.94
Previous Close Want to track COAG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
COAG closed today higher at $32.52, an increase of 8.6172% from yesterday's close, completing a monthly increase of 5.5159% or $1.7. Over the past 12 months, COAG stock gained 20.4444%.
COAG is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
Hemab Therapeutics NASDAQ: COAG Chief Executive Officer Benny Sorensen outlined the company's development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft.
Marketbeat | 4 months ago
Hemab Therapeutics Holdings, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 George Soros Soros Fund Management LLC | 25,000 | $693,000 | $745,000 | $52,000 | 7.5% |
| NM Nir Messafi Deep Track Capita LLP | 3.6M | $99.85M | $117.34M | $17.49M | 17.51% |
 Regan O'Neill Burkehill Global Management LP | 75,000 | $2.08M | $2.23M | $156,000 | 7.5% |
 Li Peng China Universal Asset Management Co. Ltd. | 3,600 | $99,792 | $107,784 | $7,992 | 8.01% |
| KJ Ken Joseph Braidwel LLP | 160,000 | $4.44M | $5.18M | $740,000 | 16.68% |
Hemab Therapeutics Holdings, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MGK Michael G. King Jr. Rodman & Renshaw | 1,458.7 | $44,329.83 | $46,590.81 | $2,260.98 | 5.1% |
Hemab Therapeutics Holdings, Inc. (COAG) FAQ
What is the stock price today?
The current price is $32.52.
On which exchange is it traded?
Hemab Therapeutics Holdings, Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is COAG.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.39B.
Has Hemab Therapeutics Holdings, Inc. ever had a stock split?
No, there has never been a stock split.
Hemab Therapeutics Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Benny Sorensen CEO | NASDAQ (NGS) Exchange | 423494103 CUSIP |
| US Country | 59 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to innovating therapies that transform the treatment of blood coagulation disorders. Committed to enhancing life and human resilience, the company operates primarily within the United States and Denmark. Hemab Therapeutics was founded in 2020 and is headquartered in Cambridge, Massachusetts. The organization emphasizes the development of advanced therapeutic solutions to address unmet medical needs in coagulation-related conditions.
Products and Services
- HMB-001: This is a bispecific antibody currently undergoing Phase 1/2 clinical development. It is designed for the prophylactic treatment of Glanzmann thrombasthenia, an inherited bleeding disorder, as well as being in Phase 2 clinical trials for addressing Factor VII deficiency, another coagulation disorder. The innovative approach of HMB-001 aims to enhance the quality of life for patients suffering from these conditions.
- HMB-002: This is a monovalent antibody that is currently in Phase 1/2 clinical development. It targets the subcutaneous prophylactic treatment of Von Willebrand disease, a prevalent hereditary bleeding disorder. HMB-002 represents a cutting-edge therapeutic option designed to mitigate bleeding risks and improve patient care.
- Preclinical and Discovery-Stage Assets: In addition to its advanced therapeutic candidates, Hemab Therapeutics is actively advancing multiple assets in preclinical and discovery stages. These efforts underscore the company’s commitment to pioneering new treatments in the field of coagulation disorders and enhancing the overall resilience of patients.
Contact Information
Address: 101 Main Street
Phone: (617) 553-3952
Website: https://www.hemab.com
2026 © Marketlog. All Rights Reserved.
